Protagonist Therapeutics, Inc. (PTGX)
PTGX Chart as of 2025-03-10
Stock Information
| CEO: | – |
| CFO: | – |
| Employees: | 126 |
| Address: | 7707 Gateway Boulevard, Newark, CA, United States |
| Country: | United States |
| Website: | https://www.protagonist-inc.com |
| Listing Date: | – |
| Founded: | – |
| Founder: | – |
| Current Price: | 55.95000076293945 USD |
| Today Change: | 11.72% |
| Outstanding Shares: | 61,384,300 |
| Volume: | 5,223,073 |
| Avg Volume: | 725,662 |
| Expert Target Price: | 62.7000 (Institutions: 0) |
| EPS: | – |
| PER: | 9.082792 |
| Dividend Date: | – |
| Last Split Date: | – |
| Last Split Factor: | – |
Key Executives
| Name | Title | Pay | Year |
|---|---|---|---|
| Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1.03M | — |
| Mr. Asif Ali | Executive VP & Chief Financial Officer | 631.04k | — |
| Dr. Suneel K. Gupta Ph.D. | Executive VP of Clinical Development | 719.21k | — |
| Mr. Mohammad Masjedizadeh Ph.D. | Executive VP & Chief Technical Officer | — | — |
| Dr. Newman Yeilding | EVP, Chief Scientific Officer | — | — |
| Mr. Matthew M. Gosling J.D. | Executive VP & General Counsel | — | — |
| Ms. Carena Spivey | Head of HR & Senior VP of Human Resources | — | — |
| Dr. Ashok Bhandari Ph.D. | Executive VP & Chief Drug Discovery and Preclinical Development Officer | — | — |
| Mr. Carter J. King | Executive Vice President of Business Development | — | — |
| Ms. Abha Bommireddi | Executive Vice President of Portfolio & Program Management | — | — |
Financials
Income Statement
| Metric | Amount |
|---|---|
| Total Revenue | 434,433,000 |
| Cost Of Revenue | – |
| Gross Profit | – |
| Operating Income | 252,843,000 |
| Net Income | 275,188,000 |
Balance Sheet
| Metric | Amount |
|---|---|
| Total Assets | 744,725,000 |
| Total Liabilities | – |
| Total Stockholder Equity | – |
Cash Flow
| Metric | Amount |
|---|---|
| Total Cash From Operating Activities | – |
| Capital Expenditures | – |
SEC Filings (Gemini Summaries)
| AccNo | Date | Summary |
|---|---|---|
| 0001104659-25-021986 | 2025-03-10 | Protagonist Therapeutics (PTGX) filed an 8-K on March 10, 2025, reporting positive clinical study results for Icotrokinra in plaque psoriasis and ulcerative colitis (UC). Press releases are included as exhibits. An updated corporate presentation is on their website. |
| 0001104659-25-021045 | 2025-03-05 | Form 4 filing by Dinesh V Patel, President & CEO of Protagonist Therapeutics (PTGX), regarding changes in beneficial ownership of securities. Earliest transaction date: 03/05/2025. |
| 0001104659-25-019516 | 2025-03-03 | Protagonist Therapeutics (PTGX) filed an 8-K on March 3, 2025, announcing positive topline results from the Phase 3 VERIFY study of rusfertide for polycythemia vera. A press release and conference call/webcast presentation are included as exhibits. |
| 0001104659-25-016166 | 2025-02-21 | Protagonist Therapeutics files S-8 to register shares for the 2016 Equity Incentive Plan (2,441,405 shares, $14,341.90 fee) and the 2016 Employee Stock Purchase Plan (300,000 shares, $1,762.33 fee). Total net fee due is $16,104.23. Evergreen provisions increase share availability. |
| 0001558370-25-001317 | 2025-02-21 | Protagonist Therapeutics SEC filing (Dec 31, 2024) covers financial reporting elements like revenue recognition, R&D, stock offerings (public & at-market), common stock, paid-in capital, retained earnings, and stock-based compensation plans (equity incentive, employee stock purchase, etc.) from 2016-2024. |
News Summary
– Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now
2025-02-12 12:51:30 | Yahoo Entertainment
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Protagonist Therapeutics, …
Link
– What is HC Wainwright’s Estimate for PTGX Q1 Earnings?
2025-02-27 06:10:57 | ETF Daily News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) – Investment analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Protagonist Therapeutics in a report released on Monday, February 24th. HC Wainwright analyst D. Tsao now a…
Link
– JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX)
2025-02-10 17:04:47 | ETF Daily News
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $58.00 price target on the stock. PTGX has been …
Link
– Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by KBC Group NV
2025-02-10 18:30:59 | ETF Daily News
KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,093 shares of the company’s stock at the end of the fourth quarter.
Link
– Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by New York State Common Retirement Fund
2025-03-04 08:34:48 | ETF Daily News
New York State Common Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 11.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 17,882 shares of th…
Link
Analysis of Today’s Rally
Protagonist Therapeutics (PTGX) experienced a notable stock rally today. This surge appears directly correlated with recent positive developments. The key driver seems to be the promising clinical trial results. These results have boosted investor confidence significantly.
The March 10th 8-K filing details positive data for Icotrokinra. The studies focused on both plaque psoriasis and ulcerative colitis. This strengthens the potential market for this drug candidate. This news follows the March 3rd announcement of positive Phase 3 results.
The Phase 3 VERIFY study highlights the effectiveness of rusfertide. This study targeted patients with polycythemia vera. These successful clinical trials significantly de-risk the company. This makes Protagonist Therapeutics more attractive to investors.
Analyst upgrades likely contributed to the rally as well. HC Wainwright increased their Q1 earnings per share estimates. JMP Securities reiterated their “Market Outperform” rating. These positive ratings reinforce the bullish sentiment.
While the New York State Common Retirement Fund reduced its holdings, the KBC Group NV increased its stake. The increased position likely signals further institutional confidence. Overall, the combination of positive clinical data and analyst support fueled the rally. This created significant positive momentum for PTGX today.
This stock has shown a change of 11.72% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.
The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.
Leave a Reply